July 21, 2017 Uncategorized

CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma

Basel, 21 July 2017 CHMP recommends EU approval of Roche’s Gazyvaro for people with previously untreated advanced follicular lymphoma Pivotal GALLIUM study demonstrated that Gazyvaro-based treatment helped people with previously untreated follicular lymphoma live significantly longer without disease progression compared to MabThera-based treatment Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the EU Committee... Read more

July 21, 2017 Uncategorized

CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer

Basel, 21 July 2017 CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential treatment option for people with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) TECENTRIQ as a potential treatment option for people with... Read more

July 21, 2017 Bio/Pharma/CRO Uncategorized

CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer

Basel, 21 July 2017 CHMP recommends EU approval for Roche’s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential treatment option for people with previously treated locally advanced or metastatic non-small cell lung cancer (NSCLC) TECENTRIQ as a potential treatment option for people with... Read more

July 17, 2017 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia

Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more

July 17, 2017 Licensing, IP, and Legal

Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia

Basel, 17 July 2017 Roche’s OCREVUS (ocrelizumab) approved for relapsing and primary progressive multiple sclerosis in Australia Second approval after the US for OCREVUS as the first and only approved treatment for people with primary progressive multiple sclerosis, a highly disabling form of MS Australia has among the highest prevalence of MS in the Southern... Read more

July 10, 2017 Bio/Pharma/CRO Product Launch

Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine

Basel, 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate... Read more

July 10, 2017 Bio/Pharma/CRO Product Launch

Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine

Basel, 10 July 2017 Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were positive, including an intra-patient comparison that showed emicizumab reduced bleed rate... Read more

July 7, 2017 PR/Corporate

Invitation to Roche Analyst Event at ISTH 2017

Basel, 07 July 2017 Invitation to Roche Analyst Event at ISTH 2017 Monday, 10 July 2017, 6:30pm CEST Roche will host an analyst briefing during the International Society on Thrombosis and Hemostasis Congress (ISTH) in Berlin 8 – 13 July 2017. Meeting Information Date: Monday, 10 July 2017 Time: 6:00pm Registration desk opens 6:30pm Start... Read more